Market Overview

Intermittent Claudication Drug Development Pipeline Analysis Report 2018 - ResearchAndMarkets.com

Share:

The "2018
Intermittent Claudication Drug Development Pipeline Analysis Report-
Companies, Drugs, Clinical Trials, Latest Developments in Intermittent
Claudication Market"
report has been added to ResearchAndMarkets.com's
offering.

An estimated 40 million people suffer from Intermittent Claudication
disease worldwide. The disease represents Plaque deposits in primary
artery limit the volume of blood supplies to legs, which results in
cramps when walking. Pain is primarily observed in calves and
occasionally in thighs and buttocks. Intermittent Claudication is often
considered as a key symptom of the peripheral arterial disease.

To assist researchers, investors and business development managers, the
publisher has come up with a comprehensive report on Intermittent
Claudication pipeline. The report provides insights into different
therapeutic candidates in preclinical, research, discovery, NDA/IND, pre
registration, phase 1, phase 2, and phase 3 trials. Drugs under
development directly and through combination with other drugs are also
included.

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Intermittent Claudication
pipeline product. Mechanism of Action and the target area of the
pipeline product are also provided. Further, clinical and preclinical
trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key
trends in Intermittent Claudication pipeline studies. The products under
development are categorized according to their development phase,
mechanism and company to provide detailed insights into the type of
drugs being developed and the stages of development.

Companies Mentioned

  • Aldagen, Inc
  • DNAVEC Corporation
  • Genovate Biotechnology
  • LTT Bio-Pharma Co.,Ltd.
  • Novartis International AG
  • Pluristem Therapeutics Inc

Key Topics Covered:

1 Table of Contents

2 Intermittent Claudication Pipeline Analysis

3 Intermittent Claudication- Company Wise Pipeline Analysis

4 Intermittent Claudication R&D Pipeline Snapshots

5 Recent Developments in Intermittent Claudication Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/2wwpfk/intermittent?w=4

View Comments and Join the Discussion!